ABSTRACT
Tacrolimus, a drug originally known as FK-506, is a relatively new immunosuppressant grouped in the same family as cyclosporin A. It was initially used orally and intravenously as an agent for prophylaxis of organ transplant rejection. It later has become of interest to dermatologists because the topical form has proven to be effective in atopic dermatitis with very few, if any, side effects. In recent times, multiple trials, especially in its topical form, are being carried out for diseases where immunosuppression could be beneficial.
